CNS Pharmaceuticals Licenses Breakthrough Technology from MD Anderson, Doubling its Drug Pipeline
CNS Pharmaceuticals, Inc. (CNSP)
Company Research
Source: PR Newswire
HOUSTON, Jan. 13, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has entered into a licensing agreement with MD Anderson to investigate WP1244, an entirely new class of DNA-binding agents designed to cross the blood brain barrier for the potential the treatment of primary and metastatic brain cancers. This agreement marks the Company's first direct relationship with MD Anderson, the largest cancer research and treatment institute in the world, and allows for the continued development of WP1244, a new class of DNA-binding agents shown to have high anti-tumor activity. WP1244 was designed using a "modular" strategy, which combines intercalation and groove-binding modes into molecules with the requisite chirality and binding-site size to impart meaningful selectivity. Previous pre-clinical tests have demonstrated the agent's ability
Show less
Read more
Impact Snapshot
Event Time:
CNSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNSP alerts
High impacting CNS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CNSP
News
- CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- CNS Pharmaceuticals Announces Pricing of $4.0 Million Public OfferingAccesswire
- Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors [Yahoo! Finance]Yahoo! Finance
- Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors Accesswire
- CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) [Yahoo! Finance]Yahoo! Finance
CNSP
Sec Filings
- 3/28/24 - Form PRE
- 2/27/24 - Form 8-K
- 2/21/24 - Form 8-K
- CNSP's page on the SEC website